Molecular Therapy - Methods & Clinical Development

Slides:



Advertisements
Similar presentations
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Advertisements

Figure 1. AsCpf1 and LbCpf1-mediated gene editing in human cells
Volume 16, Issue 3, Pages (March 2008)
Volume 3, Issue 6, Pages (June 2001)
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 6, Pages (May 2018)
Molecular Therapy - Methods & Clinical Development
Volume 2, Issue 4, Pages (October 2000)
Volume 61, Issue 1, Pages S9-S15 (January 2002)
Volume 10, Issue 1, Pages (July 2004)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 4, Pages (October 2015)
Vaccinia virus as a subhelper for AAV replication and packaging
Volume 24, Issue 7, Pages (August 2018)
Volume 22, Issue 10, Pages (October 2014)
Engineering PTEN-L for Cell-Mediated Delivery
Volume 26, Issue 1, Pages (January 2018)
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Engineering PTEN-L for Cell-Mediated Delivery
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Expression of a microRNA-Resistant Target Transgene Misrepresents the Functional Significance of the Endogenous microRNA: Target Gene Relationship  Junyan.
A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors  Qizhao Wang, Zhongren Wu, Junping Zhang, Jenni Firrman, Hongying Wei, Zhengjing.
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 11, Pages (November 2014)
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Volume 8, Issue 2, Pages (July 2014)
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
Volume 2, Issue 1, Pages (January 2014)
Revathiswari Tirughana, Marianne Z
Volume 18, Issue 1, Pages (January 2010)
Thermal Stability as a Determinant of AAV Serotype Identity
Volume 16, Issue 5, Pages (May 2008)
Molecular Therapy - Methods & Clinical Development
Volume 19, Issue 6, Pages (June 2011)
Volume 15, Issue 2, Pages (February 2007)
Volume 19, Issue 4, Pages (April 2011)
Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing  Pavel I. Ortinski, Bernadette.
Molecular Therapy - Methods & Clinical Development
Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 
Volume 23, Issue 3, Pages (March 2015)
Volume 19, Issue 6, Pages (June 2011)
Volume 22, Issue 4, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Volume 26, Issue 2, Pages (February 2018)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Effect of Genome Size on AAV Vector Packaging
Volume 22, Issue 9, Pages (September 2014)
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 17, Issue 1, Pages (January 2009)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Changyu Zheng, Bruce J. Baum  Molecular Therapy 
Volume 52, Issue 1, Pages (October 2013)
Volume 15, Issue 7, Pages (July 2007)
Volume 24, Issue 1, Pages (January 2016)
Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes  Zekun Wang, Fang Cheng, John F. Engelhardt,
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors  Yani Hu,
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
Nicole K. Paulk, Katja Pekrun, Gregory W
Volume 22, Issue 11, Pages (November 2014)
Molecular Therapy - Methods & Clinical Development
Hildegard Büning, Arun Srivastava 
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Molecular Therapy - Methods & Clinical Development Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality  Marti Cabanes-Creus, Samantha L. Ginn, Anais K. Amaya, Sophia H.Y. Liao, Adrian Westhaus, Claus V. Hallwirth, Patrick Wilmott, Jason Ward, Kimberley L. Dilworth, Giorgia Santilli, Arkadiusz Rybicki, Hiroyuki Nakai, Adrian J. Thrasher, Adrian C. Filip, Ian E. Alexander, Leszek Lisowski  Molecular Therapy - Methods & Clinical Development  Volume 12, Pages 71-84 (March 2019) DOI: 10.1016/j.omtm.2018.10.016 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Local Codon Optimization Increases DNA Shuffling but Negatively Affects Packaging Function (A) Percent identity between capsid genes of indicated wild-type (WT) AAV serotypes. (B) Parental sequence contribution analysis of sample clones isolated from AAVLib256. Parental sequences are represented by red (AAV2), green (AAV5), and blue (AAV6) lines. Size of vertical bars represents probability that individual residue was contributed by given parental vector. Black line represents the most probable composition of individual shuffled clones based on the longest sequence of identity to parental variants in a 5′ to 3′ direction. (C) Percent identity between variants codon-optimized using human codon-usage table (hco). (D and E) rAAV yield comparison using helper plasmids encoding wild-type cap genes (wtAAV2, wtAAV5, wtAAV6, and wtAAV8) and corresponding hcoAAVs in the absence (D) or presence (E) of serotype-specific AAP provided in trans. vg = vector genomes. Values in (D) and (E) are shown as mean ± SD (n = 3). Molecular Therapy - Methods & Clinical Development 2019 12, 71-84DOI: (10.1016/j.omtm.2018.10.016) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Functional Evaluation of AAVs Modified Using Localized Codon-Optimization Algorithm (A) Percent identity at the DNA level between sequences of optimized AAV2, AAV5, and AAV6 capsid genes (lcoAAV2, lcoAAV5, and lcoAAV6, respectively). (B) DNA identity tree between cap genes from wtAAVs (wtAAV2, wtAAV5, and wtAAV6, in black) and LCO cap genes (lcoAAV2, lcoAAV5, and lcoAAV6, in purple). The numbers indicate the frequency of nucleotide substitutions per site. (C) rAAV yield comparison from three independent crude productions using helper plasmids encoding optimized capsids (lcoAAV2, lcoAAV5, and lcoAAV6) (gray bars: LCO). Packaging constructs encoding wild-type cap genes (wtAAV2, wtAAV5, wtAAV6) served as controls (black bars: WT). (D) Functional comparison between recombinant AAV2, AAV5, and AAV6 (WT: black bars) and lcoAAV2, lcoAAV5, and lcoAAV6 (LCO: gray bars). HuH7 cells were transduced at an MOI = 5.0 × 103 for AAV2 and AAV6 variants and at an MOI = 5.0 × 104 for AAV5 variants, with vectors encoding EGFP under the control of a liver-specific promoter (LSP). FACS analysis of EGFP was performed 72 hr after transduction. Values in (C) and (D) are shown as mean ± SD (n = 3). Molecular Therapy - Methods & Clinical Development 2019 12, 71-84DOI: (10.1016/j.omtm.2018.10.016) Copyright © 2018 The Authors Terms and Conditions

Figure 3 AAV Shuffled Library Based on lcoAAV2, lcoAAV5, and lcoAAV6 (A) Sequence analysis of representative clones from AAVLiblco256 showing increased shuffling efficiency at the DNA level. (B) Number of individual parental segments contributing to clones from shuffled AAV library based on capsids from wtAAV2, wtAAV5, and wtAAV6 (AAVLib256) (4.37 ± 0.53, mean ± SEM) and library generated using localized codon-optimization (LCO) algorithm optimized caps (AAVLiblco256) (17.31 ± 0.57, mean ± SEM). (C) Size distribution and mean (red line) size of parental fragments contributing to clones (n = 145) from AAVLib256 (407.2 ± 44.91, mean ± SEM) and AAVLiblco256 (129.5 ± 11.6, mean ± SEM). (D) Sequence composition of clone HuH-R6C12 isolated from AAVLiblco256 library during selection screen on HuH7 cells. (E) Functional analysis of HuH-R6C12 clone. HuH7 cells were transduced with iodixanol preparations of rAAV-HuH-R6C12, control wild-type (WT) vectors (rAAV2, rAAV5, and rAAV6), and lcoAAV vectors (lcoAAV2, lcoAAV5, and lcoAAV6) at MOIs indicated. FACS analysis of EGFP was performed 72 hr after transduction. Values are shown as mean ± SD (n = 3). ****p < 0.0001. Molecular Therapy - Methods & Clinical Development 2019 12, 71-84DOI: (10.1016/j.omtm.2018.10.016) Copyright © 2018 The Authors Terms and Conditions

Figure 4 Functional Evaluation of AAV1–12 Optimized Using Localized Codon Optimization Method (A) Evaluation of lcoAAVs cap genes based on packaging efficiency. rAAV vectors produced using AAV-helper plasmids encoding corresponding wild-type cap genes were used as controls and were assigned a value of 100%. For clarity and convenience, we show again data for AAV2, AAV5, and AAV6 from Figure 2C. (B) Evaluation of the effect of AAP12 on packaging efficiency of lcoAAV12. (C) Functional assessment of rAAV vectors produced using lcoAAV and wtAAV cap genes for their ability to functionally transduce HuH7 cells. All values are shown as mean ± SD (n = 3). Molecular Therapy - Methods & Clinical Development 2019 12, 71-84DOI: (10.1016/j.omtm.2018.10.016) Copyright © 2018 The Authors Terms and Conditions

Figure 5 Parental Capsid Phylogeny, LCO-Based Enhancement of Sequence Identity, and Increased Shuffling Efficiency (A) Phylogenetic relationship among the 14 AAV variants used in the study. (B) Relative increase in percent identity between wtAAV cap genes and cap genes optimized using the LCO algorithm. Values = %homologyLCO − %homologyWT. (C) Percent identity between individual wtAAV cap genes and lcoAAV cap genes. (D and E) Changes in shuffling index between plasmid libraries (D) and packaged AAV libraries (E) generated using wtAAV cap and lcoAAV cap, with green color indicating higher and red indicating lower shuffling index. n = 40 clones per library were used in the analysis. Molecular Therapy - Methods & Clinical Development 2019 12, 71-84DOI: (10.1016/j.omtm.2018.10.016) Copyright © 2018 The Authors Terms and Conditions